| |
SACQ (170)
|
SQCQ (187)
|
|---|
|
Flare (23/56)
|
Non-flare (69/114)
|
p
|
Flare (10/29)
|
Non-flare (87/158)
|
p
|
|---|
|
AZA
|
12/23 (52.5%)
|
27/69 (39.1%)
|
0.273
|
2/10 (20%)
|
23/87 (26.4%)
|
0.659
|
|
MMF
|
5/23 (21.7%)
|
23/69 (33.3%)
|
0.295
|
1/10 (10%)
|
21/87 (24.1%)
|
0.540
|
|
MTX
|
3/23 (13.0%)
|
11/69 (15.9%)
|
1.000
|
6/10 (60%)
|
23/87 (26.4%)
|
0.067
|
|
LEF
|
2/23 (8.7%)
|
8/69 (11.6%)
|
1.000
|
5/10 (50%)
|
20/87 (23.0%)
|
0.142
|
|
CTX
|
3/23 (13.0%)
|
4/69 (5.8%)
|
0.496
|
2/10 (20%)
|
6/87 (6.9%)
|
0.412
|
|
CSA
|
3/23 (13.0%)
|
1/69 (1.4%)
|
0.077
|
0/10 (0%)
|
4/87 (4.6%)
|
1.000
|
- AZA azathioprine, MMF mycophenolate mofetil, MTX methotrexate, LEF leflunomide, CTX cyclophosphamide, CsA cyclosporin A
